Compressione pneumatica intermittente con e senza esercizio per migliorare il funzionamento nella malattia delle arterie periferiche (INTERCEDE)
Compressione pneumatica intermittente con e senza esercizio per migliorare il funzionamento nella malattia delle arterie periferiche: lo studio INTERCEDE
The INTERCEDE randomized trial will establish whether six-months of intermittent pneumatic compression combined with walking exercise improves walking endurance at six-month follow-up, compared to walking exercise + sham compression therapy, in people with lower extremity peripheral artery disease (PAD). The INTERCEDE trial will also determine whether intermittent pneumatic compression therapy improves walking endurance at 6-month follow-up, compared to a sham compression therapy. The trial will also determine whether benefits of intermittent pneumatic compression persist after intermittent pneumatic compression treatment is completed.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Walking exercise is first-line therapy for PAD. However, many PAD patients are unable or unwilling to exercise. Therefore, in people with PAD, the investigators will determine whether intermittent pneumatic compression augments the benefits of exercise and whether intermittent pneumatic compression alone improves walking performance compared to sham control. The investigators will conduct a randomized trial (2 x 2 factorial design) of 230 PAD participants randomized to one of four groups: Group A: intermittent pneumatic compression + exercise; Group B: intermittent pneumatic compression+ "no exercise" control; Group C: sham control + exercise; and Group D: sham control + "no exercise" control. The intermittent pneumatic compression and sham interventions will be delivered for six months. The primary outcome is change in six-minute walk distance at 6-month follow-up. In secondary aims, the investigators will determine whether the benefits of intermittent pneumatic compression persist even after intermittent pneumatic compression is discontinued and delineate mechanisms by which intermittent pneumatic compression affects walking performance, by measuring changes in MRI-measured calf muscle perfusion and physical activity. The investigators will determine whether intermittent pneumatic compression improves systemic endothelial function, by measuring changes in brachial artery flow-mediated dilation (FMD).
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Health
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
All participants will have PAD. PAD will be defined as follows: first, an ankle-brachial index (ABI) < or = 0.90 at the baseline study visit is an inclusion criterion for PAD. Second, potential participants with an ABI >0.90 who have vascular laboratory evidence of PAD. Vascular laboratory evidence consists of objective evidence of PAD, including toe brachial index (TBI) < or = 0.70, Duplex measure showing 70% stenosis or greater, or ABI values < 0.90. Abnormal waveforms or pulse volume recordings alone from a non-invasive vascular laboratory test will not be sufficient for enrollment. Third, potential participants with an ABI >0.90 who have angiographic evidence of PAD consisting of a stenosis of 70% or greater in a lower extremity artery.
Exclusion Criteria:
- Above- or below-knee amputation.
- Critical limb ischemia or ABI < 0.30 in the setting of ischemic symptoms at rest or physical examination findings consistent with critical limb ischemia. Some potential participants with symptoms or signs of critical limb ischemia may be excluded at the principal investigator's discretion if the ABI is 0.30 or higher.
- Wheelchair-bound.
- Current foot ulcer on bottom of foot.
- Walking is primarily limited by a symptom other than PAD.
- Failure to successfully complete the study run-in.
- Major surgery, revascularization, or orthopedic surgery in the past 3 months or planned in the next 12 months.
- Major medical illness including Parkinson's Disease, lung disease requiring oxygen, cancer requiring treatment in the previous two years, or life-threatening illness with a life expectancy of less than six months. Participants who only use oxygen at night will be potentially eligible. [NOTE: potential participants treated for cancer in the past two years may still qualify if they have had treatment for early stage cancer in the past two years and the prognosis is excellent. Potential participants treated for basal cell or squamous cell skin cancer will not be excluded.]
- Already exercising at a level consistent with exercise intervention. Current or recent participation in exercise rehabilitation (within the past three months).
- Recently diagnosed (within the past three months) with acute lower extremity deep venous thrombosis, pulmonary embolism, or severe heart failure (i.e. New York Heart Association (NYHA) Class III or IV).
- Mini-Mental Status Examination (MMSE) score <23 or dementia.
- Participation in or completion of a clinical trial in the previous three months.
- Non-English speaking.
- Increase in angina in the past month, angina at rest, or abnormal baseline treadmill stress test. Potential participants may become eligible after an abnormal baseline treadmill stress test if they have evidence of an absence of coronary ischemia based on testing (such as a stress test with imaging or a coronary angiogram) from a test performed with their own physician and if they do not have symptoms of unstable angina. The evidence of absent coronary ischemia, based on an imaging stress test or coronary angiogram, must have been performed within the previous year.
- Ongoing infection of the toes, foot, or lower extremity.
- Potential participants who started on cilostazol within the last three months. They may be evaluated for eligibility once three months have passed since beginning cilostazol.
- Significant peripheral edema, defined as 3+ or greater edema severity, as determined by the principal investigator.
- BMI >45 kg/M2
- Significant visual impairment that interferes with walking.
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: IPC + exercise
Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy. |
Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
Altri nomi:
Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration. |
|
Sperimentale: IPC + "no exercise" control
Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention |
Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
Altri nomi:
Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information. |
|
Comparatore attivo: sham control + exercise
Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy. |
Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration. The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour. |
|
Comparatore attivo: sham control + "no exercise" control
Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group. |
Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information. The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Six-minute walk distance (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression combined with exercise improves the 6-minute walk at 6-month follow-up compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Six-minute walk distance (intermittent pneumatic compression therapy alone (without exercise) vs. sham alone (without exercise)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone (without exercise) improves the 6-minute walk at 6-month follow-up, compared to the sham control alone (without exercise). |
Baseline to 6-month follow-up
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Six-minute walk distance (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves the six-minute walk at 12-month follow-up, 6 months after the intermittent pneumatic compression therapy intervention is completed, compared to exercise alone. |
Baseline to 12-month follow-up
|
|
Six-minute walk distance (IPC only v. sham only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves the six-minute walk distance at 12-month follow-up, 6 months after the intermittent pneumatic compression therapy intervention is completed, compared to the sham control. |
Baseline to 12-month follow-up
|
|
Calf muscle perfusion (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves calf muscle perfusion at 6-month follow-up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Brachial artery FMD (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves brachial artery FMD at 6-month follow-up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves physical activity measured by Actigraph activity monitor at 6-month follow-up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Calf muscle perfusion (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves calf muscle perfusion at 12-month follow-up, compared to exercise alone. |
Baseline to 12-month follow-up
|
|
Brachial artery FMD (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves brachial artery FMD at 12-month follow-up, compared to exercise alone. |
Baseline to 12-month follow-up
|
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves physical activity measured by Actigraph activity monitor at 12-month follow-up, compared to exercise alone. |
Baseline to 12-month follow-up
|
|
Calf muscle perfusion (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves calf muscle perfusion at 6-month follow-up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Brachial artery FMD (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves brachial artery FMD at 6-month follow-up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves physical activity measured by Actigraph activity monitor at 6-month follow-up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Calf muscle perfusion (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves calf muscle perfusion at 12-month follow-up, compared to the sham control. |
Baseline to 12-month follow-up
|
|
Brachial artery FMD (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves brachial artery FMD at 12-month follow-up, compared to the sham control. |
Baseline to 12-month follow-up
|
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves physical activity measured by Actigraph activity monitor at 12-month follow-up, compared to the sham control. |
Baseline to 12-month follow-up
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mitochondrial biogenesis (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves mitochondrial biogenesis (PGC-1α) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Mitochondrial activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves mitochondrial activity (Cytochrome C oxidase) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Vascular endothelial growth factor abundance (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves vascular endothelial growth factor abundance at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Anti-oxidant enzyme activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves anti-oxidant enzyme activity (MnSOD) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Immunohistochemistry-measured mitochondrial activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves immunohistochemistry-measured mitochondrial activity (COX and SDH) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Autophagy (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves autophagy (LC3, LAMP2, PARKIN) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Capillary density (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves capillary density (CD31) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Satellite cell content (intermittent pneumatic compression therapy + exercise v. exercise only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves satellite cell content (Pax7) at 6-month follow- up, compared to exercise alone. |
Baseline to 6-month follow-up
|
|
Mitochondrial biogenesis (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves mitochondrial biogenesis (PGC-1α) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Mitochondrial activity (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves mitochondrial activity (Cytochrome C oxidase) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Vascular endothelial growth factor abundance (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves vascular endothelial growth factor abundance at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Anti-oxidant enzyme activity (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves anti-oxidant enzyme activity (MnSOD) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Immunohistochemistry-measured mitochondrial activity (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves immunohistochemistry-measured mitochondrial activity (COX and SDH) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Autophagy (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves autophagy (LC3, LAMP2, PARKIN) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Capillary density (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves capillary density (CD31) at 6-month follow- up, compared to the sham control. |
Baseline to 6-month follow-up
|
|
Satellite cell content (intermittent pneumatic compression therapy only v. sham only)
Lasso di tempo: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves satellite cell content (Pax7) at 6-month follow- up, compared to the sham control |
Baseline to 6-month follow-up
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Mary McDermott, MD, Northwestern Universtiy
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Aterosclerosi
- Arteriosclerosi
- Malattie arteriose occlusive
- Malattie vascolari periferiche
- Condizioni patologiche, segni e sintomi
- Comportamento
- Segni e sintomi
- Malattia arteriosa periferica
- Claudicazione intermittente
- Attività motoria
- Attività motoria
- Movimento
- Fenomeni fisiologici muscoloscheletrici
- Fenomeni fisiologici muscoloscheletrici e neurali
- Attrezzatura e forniture
- Esercizio
- Dispositivi di compressione pneumatica intermittente
Altri numeri di identificazione dello studio
- STU00208245
- 1R01AG057693-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .